Childhood immunisation against S. pneumoniae is the most effective public health measure for preventing IPD both among vaccine recipients (direct effect), and among unimmunised populations (indirect ‘herd’ effect).
Immunisation is the only effective method of prevention. Mumps vaccine is given in the form of the combined trivalent measles-mumps-rubella (MMR) vaccine in all European countries with a first dose at or before 18 months of age. The timing of the second dose varies across countries.
In 2014, 11 069 cases of mumps were reported to TESSy. The notification rate was 2.5 cases per 100 000 population, less than half the notification rate observed in 2012 and 2013.
Illnesses caused by infectious diseases are common in children in schools or other childcare settings. Currently there is no common EU approach to the control of communicable diseases in schools or other childcare settings, and existing information is uncertain.
In July 2014, a panel of three strains of Streptococcus pneumoniae and two simulated samples of cerebrospinal fluid was sent to 30 reference laboratories in the IBD-labnet surveillance network for quality assessment testing. This report summarises the diagnostic results submitted by the participating laboratories.